Found 22 clinical trials
An Adaptive Phase II/III Two-Part Double-Blind Randomized Placebo-controlled Dose-Finding Multi-center Study of the Safety and Efficacy of NaBen as an Add-on Therapy With Clozapine for Residual Symptoms of Refractory Schizophrenia in Adults
mg/day) compared to Placebo (0 mg/day), when combined with clozapine, in improving the residual symptoms associated with refractory schizophrenia in adults, and; to determine the optimal dose to be
- 55 views
- 20 Sep, 2021
- 1 location
Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors
The goals of this study are to replicate previous findings of genetic predictors of response to clozapine and other antipsychotic drugs.
- 300 views
- 07 Nov, 2020
- 1 location
Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs
A prospective, large, pragmatic, randomized trial to study the impact of METFORMIN and healthy lifestyle intervention (LIFE) vs. LIFE alone on patient-centered outcomes of body weight, SGA-adherence and satisfaction, psychiatric symptom burden (e.g. mood/anxiety), and Quality of Life.
- 216 views
- 08 Jul, 2021
- 30 locations
Clozapine CHAMPION-ECHO Educational Study to Improve Clozapine Use.
of clozapine in people eligible for clozapine. The sessions will include: 1) active dissemination of knowledge and information by an expert "hub" followed by 2) clozapine case presentations and
- 0 views
- 26 Jan, 2021
- 1 location
Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia
This a randomized double-blind placebo controlled trial which aims to determine the beneficial effects of minocycline augmentation to clozapine in partial responders to Treatment Resistant
- 43 views
- 23 Jan, 2021
- 4 locations
Bioequivalence Study in Patients With Schizophrenia by Using Clozaril 100 mg Tablet (Clozapine) and WID-CLZ18
mg tablet (Clozapine) after oral administration in schizophrenia patients.
- 0 views
- 01 May, 2021
Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia
that once-daily dosing of antipsychotics is a viable option regardless of plasma half-life. This would apply to clozapine as well; however, there have been no studies comparing once-daily vs. twice
- 123 views
- 07 Aug, 2021
- 1 location
Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
This clinical trial will prove whether a large number of people with intellectual disability and treatment-resistant psychosis could benefit from the use of clozapine. Benefit will mean a
- 0 views
- 29 Jan, 2021
- 20 locations
Topiramate and Schizophrenia: Effects on Weight and Psychopathology
Clozapine is the sole AP agent with superiority in treatment refractory schizophrenia, but it also is associated with the greatest risk of weight gain and other metabolic abnormalities
- 14 views
- 29 Jun, 2021
- 1 location
Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer
tendency) and clinical effects in schizophrenia patients with clozapine treatment
- 1 views
- 24 Jan, 2021
- 1 location